Milwaukee Hospital Administered First Commercial Gene Therapy
Children's Wisconsin successfully treated two sisters with an FDA-approved gene therapy for hearing loss.
Updated on Sept. 19, 2026 in Special Needs
On July 20, 2026, sisters Cleo and Lennon Plumb received the FDA-approved gene therapy Otarmeni at Children's Wisconsin. They were the first patients in the United States to receive the treatment outside of a formal clinical trial setting.
Why it matters
The therapy aims to restore hearing by correcting a malfunctioning otoferlin gene that prevents the brain from processing sound waves. This milestone marks a significant step in moving gene-editing treatments from experimental clinical trials into broader clinical practice.
The procedure involves a 20-minute infusion of the gene therapy via a catheter placed in the inner ear. Approximately 50 children are born in the U.S. annually with this specific genetic mutation.
The players
Children's Wisconsin
This Milwaukee-based hospital is a pediatric medical center that serves as a regional leader in specialized child healthcare.
Cleo and Lennon Plumb
These two sisters became the first patients in the United States to receive Otarmeni outside of a clinical trial.
The details
Surgeons performed the procedure by making an incision behind the ear and inserting a catheter to deliver the medicine. The process is designed to reconstruct the patient's mutated genetic code, with doctors conducting post-surgery follow-up tests to monitor the results.
Timeline
Clinical trials for the therapy were held during 2023 and 2024.
The surgery for the sisters took place on July 20, 2026.
Follow-up hearing tests were conducted on August 25, 2026.
Culture Shift
This procedure reflects a broader societal move toward embracing personalized medicine as a standard intervention rather than a theoretical experiment. It follows the precedent established by the 2023-2024 national Otarmeni clinical trial, which proved the efficacy of the therapy before its commercial rollout.
For families dealing with genetic hearing loss, this development suggests that specialized, high-tech interventions are moving closer to becoming available at major children's hospitals. Parents should consult with specialists to determine if specific genetic mutations match the criteria for these emerging treatments.
The takeaway
This successful procedure highlights the rapid evolution of genetic medicine from small-scale trials to practical, real-world application. Families facing similar diagnoses are encouraged to maintain contact with specialized medical centers as new therapies continue to transition into broader use.
Further reading
Learn more about the latest advancements in Special Needs support and medical breakthroughs.
Source note: This article includes information reported by Channel 3000.
